Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for the treatment diseases with unmet medical needs through accelerated regulatory pathways, has entered into an agreement with Alcami Corporation, a global pharmaceutical contract development and manufacturing organization (“CDMO”). The agreement marks Tryp’s next step in the proprietary manufacturing, formulation and delivery of products for its Psilocybin-for-Neuropsychiatric Disorder, PFN(TM) (“PFN”) program. The agreement is focused on developing oral formulations for Tryp’s proprietary psilocybin active pharmaceutical ingredient (“API”), which is being manufactured by Albany Molecular Research, Inc. The announcement noted Alcami’s broad capabilities, technical expertise and ability to collaborate with customers to consistently deliver high-quality results. Tryp is tentatively planning to manufacture an initial batch of cGMP psilocybin API by September 2021, after which Alcami and Tryp will develop the analytical methods and the final formulation of Tryp’s oral psilocybin product. “Our partnership with Alcami signals the further advancement of our proprietary manufacturing of synthetic psilocybin,” said Tryp president and chief science officer Jim Gilligan, PhD, in the release. “We have been impressed with Alcami’s expertise with developing both final formulations as well as the analytical methods that will ensure the consistently excellent quality of our products.”
To view the full press release, visit https://ibn.fm/XA1zW
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing clinical-stage compounds for the treatment diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders, or PFN(TM), program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders. Tryp’s lead PFN drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than 5 million people in the United States. The company is also preparing to initiate a phase 2a clinical study for eating disorders in partnership with Dr. Jennifer Miller at the University of Florida. For more information about the company, please visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF available in the company’s newsroom at https://ibn.fm/TRYPF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.